Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma.

Literature DB >> 19029147

Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma.

David Wrench, Rachel Waters, Emanuela Carlotti, Sameena Iqbal, Janet Matthews, Marie Calaminici, John Gribben, T Andrew Lister, Jude Fitzgibbon.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2008 PMID： 19029147 PMCID： PMC2625408 DOI： 10.3324/haematol.13533

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

12 in total

1. The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia.

Authors: Thorsten Zenz; Sonja Häbe; Axel Benner; Dirk Kienle; Hartmut Döhner; Stephan Stilgenbauer
Journal: Haematologica Date: 2008-05-27 Impact factor: 9.941

2. Two polymorphic variants of wild-type p53 differ biochemically and biologically.

Authors: M Thomas; A Kalita; S Labrecque; D Pim; L Banks; G Matlashewski
Journal: Mol Cell Biol Date: 1999-02 Impact factor: 4.272

3. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.

Authors: Jodi R Alt; Timothy C Greiner; John L Cleveland; Christine M Eischen
Journal: EMBO J Date: 2003-03-17 Impact factor: 11.598

4. p53 mutations are associated with histologic transformation of follicular lymphoma.

Authors: F Lo Coco; G Gaidano; D C Louie; K Offit; R S Chaganti; R Dalla-Favera
Journal: Blood Date: 1993-10-15 Impact factor: 22.113

5. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.

Authors: Xuemei Zhang; Xiaoping Miao; Yongli Guo; Wen Tan; Yifeng Zhou; Tong Sun; Yonggang Wang; Dongxin Lin
Journal: Hum Mutat Date: 2006-01 Impact factor: 4.878

6. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.

Authors: Naoki Ohmiya; Ayumu Taguchi; Nobuyuki Mabuchi; Akihiro Itoh; Yoshiki Hirooka; Yasumasa Niwa; Hidemi Goto
Journal: J Clin Oncol Date: 2006-09-20 Impact factor: 44.544

7. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

Authors: Gareth L Bond; Kim M Hirshfield; Tomas Kirchhoff; Gabriella Alexe; Elisabeth E Bond; Harlan Robins; Frank Bartel; Helge Taubert; Peter Wuerl; William Hait; Deborah Toppmeyer; Kenneth Offit; Arnold J Levine
Journal: Cancer Res Date: 2006-05-15 Impact factor: 12.701

Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma.

1. The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia.

2. Two polymorphic variants of wild-type p53 differ biochemically and biologically.

3. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.

4. p53 mutations are associated with histologic transformation of follicular lymphoma.

5. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.

6. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.

7. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

8. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.

9. p53 mutation is associated with progression in follicular lymphomas.

10. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation.

Review 1. Host genetics in follicular lymphoma.

Review 2. Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.

3. Genetic variation in cell death genes and risk of non-Hodgkin lymphoma.

4. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.